Overview
As a committed life-long learner, I am awed by the continued advancements in the field of pediatric transplant and cellular therapy (PTCT). Following completion of my PTCT fellowship training at Duke, I have developed a career dedicated to expanding indications for PTCT and improving associated outcomes. I have a special interest in the mitigation of endotheliopathies and continue to lead global harmonization efforts related to management of toxicities of therapy. As the Division Chief of PTCT at Duke, I am committed to the ensuring our patients receive state of the art care with access to innovative research protocols that change the field. We are committed to training the next generation of physicians in our field with a commitment to global partnerships to improve care for patients across the world.
Current Duke Appointments & Affiliations
Professor of Pediatrics
·
2023 - Present
Pediatrics, Transplant and Cellular Therapy,
Pediatrics
Chief, Division of Pediatric Transplant & Cellular Therapy
·
2023 - Present
Pediatrics, Transplant and Cellular Therapy,
Pediatrics
Member of the Duke Cancer Institute
·
2023 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Erratum to 'Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome'[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9].
Journal article Transplant Cell Ther · June 2026 Full text Link to item CiteFirst in vivo hematopoietic stem cell (HSC) gene addition clinical trial: Initial results from EN-374-101 in X-linked chronic granulomatous disease (X-CGD)
Conference MOLECULAR THERAPY · May 8, 2026 Link to item CiteDefibrotide for prophylaxis of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in pediatric high-risk patients: consensus guidelines from the European Society for Blood and Marrow Transplantation (EBMT).
Journal article Bone Marrow Transplant · April 2026 SOS/VOD is a life-threatening complication of hematopoietic stem cell transplantation, especially in children, with incidences reaching up to 15-20%. Despite efforts, SOS/VOD remains unpredictable with significant morbidity and mortality. High-risk criteri ... Full text Open Access Link to item CiteRecent Grants
A Phase 1/2, Open-Label, Basket Study of Afamitresgene Autoleucel in Pediatric Subjects with MAGE-A4 Positive Tumors
Clinical TrialPrincipal Investigator · Awarded by Adaptimmune LLC · 2024 - 2038CYTB323L12201
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2026 - 2034CYTB323J12201 5044 J
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2026 - 2030View All Grants
Education
St. George's University, School of Medicine (West Indies) ·
2003
M.D.
Adelphi University ·
1999
B.S.